Suggestions
Tanay Tandon
CEO at Athelas
Tanay Tandon is a prominent figure in the fields of machine learning and biotechnology, currently serving as the Co-founder and CEO of Athelas, a company focused on developing innovative healthcare solutions. He has held this position since June 2016, where he has been instrumental in leveraging technology to enhance medical diagnostics and patient care.
Education and Early Career
Tanay Tandon completed his education at Stanford University, where he was involved in research within the AI department from June 2013 to September 2016. His academic background laid a strong foundation for his future endeavors in technology and healthcare innovation.
Professional Experience
In addition to his role at Athelas, Tandon recently became the Chief Executive Officer of Commure in October 2023. His previous experience includes positions such as a researcher at MetaMind and a software engineer at Wit.ai, showcasing his extensive background in software development and artificial intelligence.
Achievements and Recognition
Tandon has received numerous accolades throughout his career, including awards for his research projects in machine learning and computer science. Notably, he was recognized as a winner at Y Combinator's Hackathon for developing a portable blood analysis tool that integrates computer vision with microscopy.
Personal Insights
Tanay is multilingual, fluent in English, Hindi, and possesses limited proficiency in Spanish. His diverse skill set and leadership roles reflect his commitment to advancing technology in healthcare, making significant contributions to the industry through Athelas and Commure.
For more detailed professional insights, you can view his LinkedIn profile here .1
Highlights
Incredible to see the legendary @qasar on the cover of @Forbes today. @dpcbod and I (and many other founders) owe our careers to him. https://t.co/so7kDO8VkC

Announcing $200mm from @generalcatalyst CVF today! We will be accelerating RCM, Ambient, and Agents growth. Goal is to go from processing billions to tens of billions of healthcare dollars in the next 24 months
